ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.businesswire.com/news/home/20220425006006/en/ILiAD-Biotechnologies-Receives-NIH-Grant-to-Develop-Novel-Tuberculosis-Vaccine-using-proprietary-B-Tech-Vector-Platform
Research Institution
ILiAD Biotechnologies
Short Title
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform
Content Coordinator
Claudia Wair
Content Manager
Kathy Donbeck